Exploiting the potential of molecular profiling in Parkinson’s disease: current practice and future probabilities

References

• de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM. A population perspective on diagnostic criteria for Parkinson’s disease. Neurology48(5), 1277–1281 (1997).
   PubMed Web of Science ®Google Scholar
• Peters CM, Gartner CE, Silburn PA, Mellick GD. Prevalence of Parkinson’s disease in metropolitan and rural Queensland: a general practice survey. J. Clin. Neurosci.13(3), 343–348 (2006).
   PubMedGoogle Scholar
• de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology63(7), 1240–1244 (2004).
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology68(5), 384–386 (2007).
   PubMed Web of Science ®Google Scholar
• Findley LJ. The economic impact of Parkinson’s disease. Parkinsonism Relat. Disord.13(Suppl.), S8–S12 (2007).
   PubMed Web of Science ®Google Scholar
• Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson’s disease. Mov. Disord.20(11), 1449–1454 (2005).
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24(2), 197–211 (2003).
   PubMed Web of Science ®Google Scholar
• Cookson MR, Hardy J, Lewis PA. Genetic neuropathology of Parkinson’s disease. Int. J. Clin. Exp. Pathol.1(3), 217–231 (2008).
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology57(8), 1497–1499 (2001).
   PubMed Web of Science ®Google Scholar
• Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol.56(1), 33–39 (1999).
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico–pathological study of 100 cases [see comments]. J. Neurol. Neurosurg. Psychiatry55(3), 181–184 (1992).
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain125(Pt 4), 861–870 (2002).
   PubMed Web of Science ®Google Scholar
• Sander C. Genomic medicine and the future of health care. Science287(5460), 1977–1978 (2000).
   PubMed Web of Science ®Google Scholar
• De Gruttola VG, Clax P, DeMets DL et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health Workshop. Control. Clin. Trials22(5), 485–502 (2001).
   PubMedGoogle Scholar
• Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology38(8), 1237–1244 (1988).
   PubMed Web of Science ®Google Scholar
• Haehner A, Boesveldt S, Berendse HW et al. Prevalence of smell loss in Parkinson’s disease – a multicenter study. Parkinsonism Relat. Disord.15(7), 490–494 (2009).
   PubMedGoogle Scholar
• Haehner A, Hummel T, Reichmann H. Olfactory dysfunction as a diagnostic marker for Parkinson’s disease. Expert Rev. Neurother.9(12), 1773–1779 (2009).
   PubMed Web of Science ®Google Scholar
• Hawkes C. Olfaction in neurodegenerative disorder. Adv. Otorhinolaryngol.63, 133–151 (2006).
   PubMedGoogle Scholar
• Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M. Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci. Ther.15(2), 157–182 (2009).
   PubMedGoogle Scholar
• Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66(7), 968–975 (2006).
   PubMed Web of Science ®Google Scholar
• Lees AJ. The Parkinson chimera. Neurology72(7 Suppl.), S2–S11 (2009).
   PubMed Web of Science ®Google Scholar
• Klein C, Schneider SA, Lang AE. Hereditary parkinsonism: Parkinson disease look-alikes – an algorithm for clinicians to “PARK” genes and beyond. Mov. Disord.24(14), 2042–2058 (2009).
   PubMedGoogle Scholar
• Mehta SH, Morgan JC, Sethi KD. Neuroimaging and transcranial ultrasonography in Parkinson’s disease. Curr. Neurol. Neurosci. Rep.8(4), 297–303 (2008).
   PubMedGoogle Scholar
• Berg D, Becker G, Zeiler B et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology53(5), 1026–1031 (1999).
   PubMed Web of Science ®Google Scholar
• Berg D, Behnke S, Walter U. Application of transcranial sonography in extrapyramidal disorders: updated recommendations. Ultraschall. Med.27(1), 12–19 (2006).
   PubMedGoogle Scholar
• Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol.7(11), 1044–1055 (2008).
   PubMed Web of Science ®Google Scholar
• Hirayama M, Hakusui S, Koike Y et al. A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J. Auton. Nerv. Syst.53(2–3), 230–234 (1995).
   PubMedGoogle Scholar
• Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry76(2), 249–251 (2005).
   PubMedGoogle Scholar
• Oka H, Yoshioka M, Morita M et al. Reduced cardiac 123I-MIBG uptake reflects cardiac sympathetic dysfunction in Lewy body disease. Neurology69(14), 1460–1465 (2007).
   PubMed Web of Science ®Google Scholar
• Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson’s disease and related disorders. Mov. Disord.24(Suppl. 2), S732–S741 (2009).
   PubMed Web of Science ®Google Scholar
• Siderowf A, Stern MB. Preclinical diagnosis of Parkinson’s disease: are we there yet? Curr. Neurol. Neurosci. Rep.6(4), 295–301 (2006).
   PubMed Web of Science ®Google Scholar
• Siderowf A, Stern MB. Premotor Parkinson’s disease: clinical features, detection, and prospects for treatment. Ann. Neurol.64(Suppl. 2), S139–S147 (2008).
   PubMedGoogle Scholar
• Stern MB. The preclinical detection of Parkinson’s disease: ready for prime time? Ann. Neurol.56(2), 169–171 (2004).
   PubMedGoogle Scholar
• Poewe W, Scherfler C, Tolosa E, Marek K. Supplement neuroimaging movement disorders. Mov. Disord.24(Suppl. 2), S655 (2009).
   PubMedGoogle Scholar
• Belin AC, Westerlund M. Parkinson’s disease: a genetic perspective. FEBS J.275(7), 1377–1383 (2008).
   PubMedGoogle Scholar
• Klein C. Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch. Neurol.63(3), 328–334 (2006).
   PubMedGoogle Scholar
• Klein C, Schlossmacher MG. The genetics of Parkinson disease: implications for neurological care. Nat. Clin. Pract. Neurol.2(3), 136–146 (2006).
   PubMedGoogle Scholar
• Paulson HL. Diagnostic testing in neurogenetics. Principles, limitations, and ethical considerations. Neurol. Clin.20(3), 627–643, v (2002).
   PubMed Web of Science ®Google Scholar
• McInerney-Leo A. Genetic testing in Parkinson’s disease. Mov. Disord.20(7), 908–909 (2005).
   PubMedGoogle Scholar
• Harbo HF, Finsterer J, Baets J et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington’s disease, Parkinson’s disease and dystonias. Eur. J. Neurol.16(7), 777–785 (2009).
   PubMed Web of Science ®Google Scholar
• Scherzer CR. Chipping away at diagnostics for neurodegenerative diseases. Neurobiol. Dis.35(2), 148–156 (2009).
   PubMedGoogle Scholar
• Hennecke G, Scherzer CR. RNA biomarkers of Parkinson’s disease: developing tools for novel therapies. Biomark. Med.2(1), 41–53 (2008).
   PubMedGoogle Scholar
• Schadt EE, Lamb J, Yang X et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat. Genet.37(7), 710–717 (2005).
   PubMed Web of Science ®Google Scholar
• Marek K, Jennings D, Tamagnan G, Seibyl J. Biomarkers for Parkinson’s [corrected] disease: tools to assess Parkinson’s disease onset and progression. Ann. Neurol.64(Suppl. 2), S111–S121 (2008).
   PubMed Web of Science ®Google Scholar
• Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J. Lab. Clin. Med.147(3), 126–132 (2006).
   PubMed Web of Science ®Google Scholar
• Mohr S, Liew CC. The peripheral-blood transcriptome: new insights into disease and risk assessment. Trends Mol. Med.13(10), 422–432 (2007).
   PubMed Web of Science ®Google Scholar
• Seyfert S, Kunzmann V, Schwertfeger N, Koch HC, Faulstich A. Determinants of lumbar CSF protein concentration. J. Neurol.249(8), 1021–1026 (2002).
   PubMed Web of Science ®Google Scholar
• Hong Z, Shi M, Chung KA et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain133(Pt 3), 713–726 (2010).
   PubMed Web of Science ®Google Scholar
• Soldner F, Hockemeyer D, Beard C et al. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell136(5), 964–977 (2009).
   PubMed Web of Science ®Google Scholar
• Matigian N, Abrahamsen G, Sutharsan R et al. Disease-specific, neurosphere-derived cells as models for brain disorders. Dis. Model. Mech. DOI: 10.1242/dmm.005447 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Lederberg J, McCray A. ‘Ome sweet ‘omics – a genealogical treasury of words. The Scientist15(7), 8 (2001).
   Web of Science ®Google Scholar
• Pankratz N, Foroud T. Genetics of Parkinson disease. Genet. Med.9(12), 801–811 (2007).
   PubMed Web of Science ®Google Scholar
• Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. Mutat.31(7), 763–780 (2010).
   PubMed Web of Science ®Google Scholar
• Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev. Mol. Med.11, e22 (2009).
   PubMed Web of Science ®Google Scholar
• Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C. The genetics of Parkinson’s syndromes: a critical review. Curr. Opin. Genet. Devel.19(3), 254–265 (2009).
   PubMed Web of Science ®Google Scholar
• Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet.18(R1), R48–R59 (2009).
   PubMed Web of Science ®Google Scholar
• Nichols WC, Kissell DK, Pankratz N et al. Variation in GIGYF2 is not associated with Parkinson disease. Neurology72(22), 1886–1892 (2009).
   PubMedGoogle Scholar
• Kruger R, Sharma M, Riess O et al. A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson’s disease. Neurobiol. Aging DOI: 10.1016/j.neurobiolaging.2009.11.021 (2009) (Epub ahead of print).
   Google Scholar
• Prestel J, Sharma M, Leitner P et al. PARK11 is not linked with Parkinson’s disease in European families. Eur. J. Hum. Genet.13(2), 193–197 (2005).
   PubMed Web of Science ®Google Scholar
• Wirdefeldt K, Burgess CE, Westerberg L, Payami H, Schalling M. A linkage study of candidate loci in familial Parkinson’s disease. BMC Neurol.3, 6 (2003).
   PubMedGoogle Scholar
• Fung HC, Scholz S, Matarin M et al. Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol.5(11), 911–916 (2006).
   PubMed Web of Science ®Google Scholar
• Maraganore DM, de Andrade M, Lesnick TG et al. High-resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet.77(5), 685–693 (2005).
   PubMed Web of Science ®Google Scholar
• Elbaz A, Nelson LM, Payami H et al. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson’s disease: a large-scale international study. Lancet Neurol.5(11), 917–923 (2006).
   PubMed Web of Science ®Google Scholar
• Evangelou E, Maraganore DM, Annesi G et al. Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson’s disease: large-scale collaborative study. Am. J. Med. Genet. B Neuropsychiatr. Genet.153B(1), 220–228 (2009).
   Google Scholar
• Latourelle JC, Pankratz N, Dumitriu A et al. Genomewide association study for onset age in Parkinson disease. BMC Med. Genet.10, 98 (2009).
   PubMedGoogle Scholar
• Pankratz N, Wilk JB, Latourelle JC et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet.124(6), 593–605 (2009).
   PubMed Web of Science ®Google Scholar
• Satake W, Nakabayashi Y, Mizuta I et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat. Genet.41(12), 1303–1307 (2009).
   PubMed Web of Science ®Google Scholar
• Simon-Sanchez J, Schulte C, Bras JM et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat. Genet.41(12), 1308–1312 (2009).
   PubMed Web of Science ®Google Scholar
• Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl Acad. Sci. USA103(15), 5923–5928 (2006).
   PubMed Web of Science ®Google Scholar
• Marshall E. Getting the noise out of gene arrays. Science306(5696), 630–631 (2004).
   PubMed Web of Science ®Google Scholar
• Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet365(9458), 488–492 (2005).
   PubMed Web of Science ®Google Scholar
• Amino T, Uchihara T, Tsunekawa H et al. Myocardial nerve fibers are preserved in MPTP-treated mice, despite cardiac sympathetic dysfunction. Neurosci. Res.60(3), 314–318 (2008).
   PubMedGoogle Scholar
• Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis.9(3), 293–348 (2006).
   PubMed Web of Science ®Google Scholar
• Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord.11(8), 493–498 (2005).
   PubMed Web of Science ®Google Scholar
• Sutherland GT, Matigian NA, Chalk AM et al. A cross-study transcriptional analysis of Parkinson’s disease. PloS ONE4(3), e4955 (2009).
   PubMed Web of Science ®Google Scholar
• Scherzer CR, Grass JA, Liao Z et al. GATA transcription factors directly regulate the Parkinson’s disease-linked gene α-synuclein. Proc. Natl Acad. Sci. USA105(31), 10907–10912 (2008).
   PubMed Web of Science ®Google Scholar
• Cantuti-Castelvetri I, Keller-McGandy C, Bouzou B et al. Effects of gender on nigral gene expression and Parkinson disease. Neurobiol. Dis.26(3), 606–614 (2007).
   PubMedGoogle Scholar
• Simunovic F, Yi M, Wang Y et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology. Brain132(Pt 7), 1795–1809 (2009).
   PubMed Web of Science ®Google Scholar
• Salmi J, Nyman TA, Nevalainen OS, Aittokallio T. Filtering strategies for improving protein identification in high-throughput MS/MS studies. Proteomics9(4), 848–860 (2009).
   PubMedGoogle Scholar
• Dunn MJ. PROTEOMICS Reviews 2009. Proteomics9(4), 804–807 (2009).
   PubMedGoogle Scholar
• Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteomics4(12), 3943–3952 (2004).
   PubMed Web of Science ®Google Scholar
• Pan S, Rush J, Peskind ER et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J. Proteome Res.7(2), 720–730 (2008).
   PubMed Web of Science ®Google Scholar
• Xia Q, Liao L, Cheng D et al. Proteomic identification of novel proteins associated with Lewy bodies. Front. Biosci.13, 3850–3856 (2008).
   PubMed Web of Science ®Google Scholar
• Pienaar IS, Dexter DT, Burkhard PR. Mitochondrial proteomics as a selective tool for unraveling Parkinson’s disease pathogenesis. Expert Rev. Proteomics7(2), 205–226 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol.129(4), 526–529 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang J, Goodlett DR, Quinn JF et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis.7(2), 125–133; discussion 173–180 (2005).
   PubMed Web of Science ®Google Scholar
• Sinha A, Srivastava N, Singh S et al. Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson’s disease patients: a proteomic approach. Clin. Chim. Acta400(1–2), 14–20 (2009).
   PubMed Web of Science ®Google Scholar
• Goldknopf IL, Bryson JK, Strelets I et al. Abnormal serum concentrations of proteins in Parkinson’s disease. Biochem. Biophys. Res. Commun.389(2), 321–327 (2009).
   PubMedGoogle Scholar
• Bogdanov M, Matson WR, Wang L et al. Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain131(Pt 2), 389–396 (2008).
   PubMed Web of Science ®Google Scholar
• Dufek M, Hamanova M, Lokaj J et al. Serum inflammatory biomarkers in Parkinson’s disease. Parkinsonism Relat. Disord.15(4), 318–320 (2009).
   PubMed Web of Science ®Google Scholar
• Schwarzschild MA, Schwid SR, Marek K et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol.65(6), 716–723 (2008).
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson’s disease. Am. J. Epidemiol.166(5), 561–567 (2007).
   PubMed Web of Science ®Google Scholar
• Chen H, O’Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am. J. Epidemiol.167(1), 90–95 (2008).
   PubMed Web of Science ®Google Scholar
• Bharucha KJ, Friedman JK, Vincent AS, Ross ED. Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s disease. J. Neurol.255(12), 1957–1962 (2008).
   PubMed Web of Science ®Google Scholar
• Lu M, Faull KF, Whitelegge JP et al. Proteomics and mass spectrometry for cancer biomarker discovery. Biomark. Insights2, 347–360 (2007).
   PubMedGoogle Scholar
• Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol.16(9), 373–378 (1998).
   PubMed Web of Science ®Google Scholar
• Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis.35(2), 165–176 (2009).
   PubMed Web of Science ®Google Scholar
• Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol.22(5), 245–252 (2004).
   PubMed Web of Science ®Google Scholar
• Brindle JT, Antti H, Holmes E et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med.8(12), 1439–1444 (2002).
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology34(1), 173–186 (2009).
   PubMed Web of Science ®Google Scholar
• Shi H, Vigneau-Callahan KE, Matson WR, Kristal BS. Attention to relative response across sequential electrodes improves quantitation of coulometric array. Anal. Biochem.302(2), 239–245 (2002).
   PubMedGoogle Scholar
• Vigneau-Callahan KE, Shestopalov AI, Milbury PE, Matson WR, Kristal BS. Characterization of diet-dependent metabolic serotypes: analytical and biological variability issues in rats. J. Nutr.131(3), 924S–932S (2001).
   Google Scholar
• Johansen KK, Wang L, Aasly JO et al. Metabolomic profiling in LRRK2-related Parkinson’s disease. PloS ONE4(10), e7551 (2009).
   Web of Science ®Google Scholar
• Ahmed SS, Santosh W, Kumar S, Christlet HT. Metabolic profiling of Parkinson’s disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J. Biomed. Sci.16(1), 63 (2009).
   PubMed Web of Science ®Google Scholar
• Andreadou E, Nikolaou C, Gournaras F et al. Serum uric acid levels in patients with Parkinson’s disease: their relationship to treatment and disease duration. Clin. Neurol. Neurosurg.111(9), 724–728 (2009).
   PubMedGoogle Scholar
• Ascherio A, LeWitt PA, Xu K et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol.66(12), 1460–1468 (2009).
   PubMed Web of Science ®Google Scholar
• Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J. Pharmacol. Exp. Ther.324(1), 1–7 (2008).
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer4(4), 309–314 (2004).
   PubMed Web of Science ®Google Scholar
• Katz MH. Multivariable analysis: a primer for readers of medical research. Ann. Intern. Med.138(8), 644–650 (2003).
   PubMed Web of Science ®Google Scholar
• Geschwind DH, Konopka G. Neuroscience in the era of functional genomics and systems biology. Nature461(7266), 908–915 (2009).
   PubMed Web of Science ®Google Scholar
• Margulies M, Egholm M, Altman WE et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature437(7057), 376–380 (2005).
   PubMed Web of Science ®Google Scholar
• Shendure J, Porreca GJ, Reppas NB et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science309(5741), 1728–1732 (2005).
   PubMed Web of Science ®Google Scholar
• Eid J, Fehr A, Gray J et al. Real-time DNA sequencing from single polymerase molecules. Science323(5910), 133–138 (2009).
   PubMed Web of Science ®Google Scholar
• Marder KS, Tang MX, Mejia-Santana H et al. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch. Neurol.67(6), 731–738 (2010).
   PubMedGoogle Scholar
• Ibanez P, Lesage S, Janin S et al. α-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch. Neurol.66(1), 102–108 (2009).
   PubMed Web of Science ®Google Scholar
• Singleton AB, Farrer M, Johnson J et al. α-synuclein locus triplication causes Parkinson’s disease. Science302(5646), 841 (2003).
   PubMed Web of Science ®Google Scholar
• Voutsinas GE, Stavrou EF, Karousos G et al. Allelic imbalance of expression and epigenetic regulation within the α-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease. Hum. Mutat.31(6), 685–691 (2010).
   PubMedGoogle Scholar
• Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J. Neuropathol. Exp. Neurol.68(8), 880–891 (2009).
   PubMed Web of Science ®Google Scholar
• Graeber MB. Biomarkers for Parkinson’s disease. Exp. Neurol.216(2), 249–253 (2009).
   PubMed Web of Science ®Google Scholar
• Myers AJ, Gibbs JR, Webster JA et al. A survey of genetic human cortical gene expression. Nat. Genet.39(12), 1494–1499 (2007).
   PubMed Web of Science ®Google Scholar
• Hovatta I, Zapala MA, Broide RS et al. DNA variation and brain region-specific expression profiles exhibit different relationships between inbred mouse strains: implications for eQTL mapping studies. Genome Biol.8(2), R25 (2007).
   Google Scholar
• Hauser MA, Li YJ, Takeuchi S et al. Genomic convergence: identifying candidate genes for Parkinson’s disease by combining serial analysis of gene expression and genetic linkage. Hum. Mol. Genet.12(6), 671–677 (2003).
   PubMedGoogle Scholar
• Lesnick TG, Papapetropoulos S, Mash DC et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet.3(6), e98 (2007).
   PubMed Web of Science ®Google Scholar
• Noureddine MA, Li YJ, van der Walt JM et al. Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. Mov. Disord.20(10), 1299–1309 (2005).
   PubMedGoogle Scholar
• Liang X, Slifer M, Martin ER et al. Genomic convergence to identify candidate genes for Alzheimer disease on chromosome 10. Hum. Mutat.30(3), 463–471 (2009).
   PubMedGoogle Scholar
• Webster JA, Gibbs JR, Clarke J et al. Genetic control of human brain transcript expression in Alzheimer disease. Am. J. Hum. Genet.84(4), 445–458 (2009).
   PubMedGoogle Scholar
• Elstner M, Morris CM, Heim K et al. Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson’s disease gene. Ann. Neurol.66(6), 792–798 (2009).
   PubMedGoogle Scholar
• Scholz B, Svensson M, Alm H et al. Striatal proteomic analysis suggests that first L-DOPA dose equates to chronic exposure. PloS ONE3(2), e1589 (2008).
   Google Scholar
• Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P α-synuclein transgenic mice – a model of familial Parkinson’s disease. Neurobiol. Dis.18(3), 492–498 (2005).
   PubMed Web of Science ®Google Scholar
• Van Laar VS, Dukes AA, Cascio M, Hastings TG. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol. Dis.29(3), 477–489 (2008).
   PubMed Web of Science ®Google Scholar
• Smith DJ. Mitochondrial dysfunction in mouse models of Parkinson’s disease revealed by transcriptomics and proteomics. J. Bioenerg. Biomembr.41(6), 487–491 (2009).
   PubMed Web of Science ®Google Scholar
• Kim ST, Moon W, Chae Y, Kim YJ, Lee H, Park HJ. The effect of electroacupuncture for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced proteomic changes in the mouse striatum. J. Physiol. Sci.60(1), 27–34 (2010).
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Sagi Y, Drigues N, Youdim MB. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain. J. Neural. Transm.116(11), 1457–1472 (2009).
   PubMedGoogle Scholar
• Ichibangase T, Saimaru H, Takamura N et al. Proteomics of Caenorhabditis elegans over-expressing human α-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson’s disease stages. Biomed. Chromatogr.22(3), 232–234 (2008).
   PubMed Web of Science ®Google Scholar
• Park J, Kim Y, Chung J. Mitochondrial dysfunction and Parkinson’s disease genes: insights from Drosophila.Dis. Model. Mech.2(7–8), 336–340 (2009).
   PubMed Web of Science ®Google Scholar
• Scherzer CR, Jensen RV, Gullans SR, Feany MB. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson’s disease. Hum. Mol. Genet.12(19), 2457–2466 (2003).
   PubMedGoogle Scholar
• Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson’s disease. Neuron66(5), 646–661 (2010).
   PubMed Web of Science ®Google Scholar